Gordon M. Saul

Gordon M. Saul

Director/Board Member at
Stanford Byers Center for Biodesign
Health Technology
Consumer Services
Finance

Profile

Mr. Gordon M.
Saul
is Executive-in-Residence at InterWest Partners and Executive-in-Residence at Synvascular, Inc. He is on the Board of Directors at On Demand Therapeutics, Inc. Mr. Saul has extensive years of startup and business development experience in the pharmaceutical and medical device areas.
Prior to joining InterWest in 2003, he was a co-founder, board member and senior vice president of business development and marketing for PowderJect Pharmaceuticals, a publicly traded drug delivery company acquired by Chiron Corporation in 2003.
Prior to PowderJect, he held business development roles at ALZA Corporation and Advanced Cardiovascular Systems, a division of Guidant Corp.
He has also worked in Japan in the financial services industry and in management consulting for The Boston Consulting Group.
Mr. Saul received an A.B. in engineering sciences from Dartmouth College and an M.B.A. from Stanford University.

Gordon M. Saul active positions

CompaniesPositionStart
Director/Board Member -

Former positions of Gordon M. Saul

CompaniesPositionEnd
Corporate Officer/Principal -
Corporate Officer/Principal -
Director/Board Member -
ALZA CORPORATION Corporate Officer/Principal -
Director/Board Member -
See the detail of Gordon M. Saul's experience

Training of Gordon M. Saul

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

7

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Commercial Services

  1. Stock Market
  2. Insiders
  3. Gordon M. Saul
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!